Inhibikase Therapeutics opened lower at $1.59, compared with its previous close of $1.63. In the last trading session, the stock traded between $1.50 and $1.59. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Inhibikase Therapeutics is now worth
$ 12.60
Resulting in a loss of
$ 87.40 (87.40%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.10 (-5.83%)
Day High
$1.59
Day Low
$1.50
Day Open
$1.59
Prev Close
$1.63
Volume
5,49,033
1W Return
-1.92%
1M Return
-16.80%
3M Return
-37.22%
6M Return
-24.38%
1Y Return
-6.40%
Market Cap ($ Mn)
215
PE Ratio
-
PB Ratio
2.08
PEG Ratio
-
ROE
-47.64%
ROCE
-51.31%
EPS (TTM)
$-0.15
1 Week
-1.92%
1 Month
-16.80%
3 Months
-37.22%
6 Months
-24.38%
9 Months
-10.23%
Inhibikase Therapeutics appoints Scott Wasserman to board of directors
Scott M. Wasserman, MD, joined Inhibikase Therapeutics' Board on October 19, 2026. Dennis Berman resigned from the Board concurrently with Wasserman's appointment. Wasserman previously led global development of Repatha and Evenity at Amgen Inc. Inhibikase is advancing IKT-001 through the Phase 3 IMPROVE-PAH study for PAH.
23 days agoInhibikase Therapeutics grants 128,000 stock options to new hires
Inhibikase Therapeutics granted 128,000 non-qualified stock options to two new non-executive employees. The exercise price is set at $2.055 per share, equal to the closing price on September 30, 2026. Options vest with 25% on the first anniversary and the remaining 75% over 36 months. The grants comply with Nasdaq Listing Rule 5635(c)(4) as a material inducement for hiring.
1mo agoInhibikase Q2 EPS of $(0.11) meets analyst consensus estimates
Inhibikase Therapeutics reported a Q2 net loss of $19.6 million, or $(0.11) per share, which met analyst consensus. The loss widened due to increased R&D spending for its Phase 3 PAH program. The company raised $50 million to fund operations.
3mo agoInhibikase Therapeutics secures FDA orphan drug status for IKT-001 in PAH
Inhibikase Therapeutics secured FDA Orphan Drug Designation for IKT-001 on July 23, 2026, for treating Pulmonary Arterial Hypertension. The designation offers significant incentives, including seven years of market exclusivity and tax credits, while the company actively enrolls patients in its pivotal Phase 3 IMPROVE-PAH trial across 180 sites globally.
3mo agoInhibikase raises $50M through sale of 25M shares
Inhibikase Therapeutics sold 25,000,000 shares to RA Capital Management for $50 million gross proceeds via an at-the-market facility. The funds will support operations through the topline data readout in Part B of the Phase 3 IMPROVE-PAH study, contingent on the exercise of outstanding warrants.
4mo agoInhibikase grants $2.03 stock options to seven new hires
Inhibikase Therapeutics granted 981,243 stock options to seven new employees at $2.03 per share, effective June 30, 2026. The options vest over four years under Nasdaq Rule 5635(c)(4). The Company focuses on PAH treatments, with its lead candidate IKT-001 in Phase 3 trials.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Inhibikase Therapeutics is now worth
$ 12.60
Resulting in a loss of
$ 87.40 (87.40%)
Note: Past profits do not guarantee future returns.
